Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to irinotecan combination chemotherapy
- 1 December 2009
- journal article
- research article
- Published by Taylor & Francis in Biomarkers
- Vol. 15 (3) , 243-248
Abstract
Oxaliplatin (OXA)-induced carcinoembryonic antigen (CEA) surge was reported to be associated with a clinical benefit. The aim of this study was to investigate the phenomenon of CEA surge in irinotecan-based chemotherapy. We retrospectively reviewed 132 patients with metastatic colorectal cancer treated with irinotecan-based chemotherapy. Incidence of a CEA surge and chemotherapy efficacy were investigated. Eleven of 99 eligible patients (11.1%) had CEA surges. None of the 11 patients showed progressive disease (four had a partial response, seven had stable disease). A CEA surge can be induced by irinotecan-based chemotherapy. An early increase in CEA after irinotecan-based chemotherapy does not usually indicate progression of disease and failure of therapy, and should not lead to a change of chemotherapy.Keywords
This publication has 16 references indexed in Scilit:
- ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal CancerJournal of Clinical Oncology, 2006
- Chemotherapy-Induced Carcinoembryonic Antigen Surge in Patients with Metastatic Colorectal CancerOncology, 2006
- Systemic Therapy for Colorectal CancerNew England Journal of Medicine, 2005
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Drug-induced increase of carcinoembryonic antigen expression in cancer cellsPharmacological Research, 2004
- Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugsJournal of Cancer Research and Clinical Oncology, 2003
- CEA and CA19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA)Annals of Oncology, 2001
- Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion moleculeCell, 1989
- Carcinoembryonic AntigenAnnals of Internal Medicine, 1986